Researchers discover that activating innate immunity in the gastrointestinal tract reduces disease pathology in ulcerative colitis
01 oct. 2018 07h00 HE
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease
18 avr. 2018 16h16 HE
|
Qu Biologics
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a Vancouver, Canada-based biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique...
Response to Novel Immune Therapy for Ulcerative Colitis Associated with Genetic and Immune Biomarkers
03 oct. 2017 12h16 HE
|
Qu Biologics
VANCOUVER, British Columbia , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies...